RE:RE:Big Pharma is facing a looming $236 Billion patent cliffpelareorep is a biologic which would receive 12 years of FDA market exclusivity upon the drug's approval that would extend any patent expiration and therefore would be attractive to any Big Pharma whose own patent portfolio is endangered of expiration and is looking to combine ONCY's pelareorep with one of their high value oncology products, such as Pfizer's Ibrance (CDK 4/6 inhibitor), to extend the life of that product from generic competition even before Ibrance loses patent protection in 2027.